Cost‑effectiveness of precision cancer medicine‑current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review)

  • Authors:
    • Konstantinos Christofyllakis
    • Joerg Thomas Bittenbring
    • Lorenz Thurner
    • Manfred Ahlgrimm
    • Stephan Stilgenbauer
    • Moritz Bewarder
    • Dominic Kaddu‑Mulindwa
  • View Affiliations

  • Published online on: November 25, 2021     https://doi.org/10.3892/mco.2021.2453
  • Article Number: 21
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Precision cancer medicine (PCM) is an emerging paradigm in oncology, which includes tumour comprehensive genomic profiling (CGP) to enable molecularly guided therapy. However, cost‑effectiveness analyses of PCM are faced with several challenges and, thus, its cost‑effectiveness remains unclear. Early trials using only molecularly guided therapy were faced with the challenge of providing adequate measures of outcome, which probably explains the modest treatment benefits demonstrated. Endpoints like the progression‑free survival (PFS)2/PFS1 ratio may assist in overcoming this issue. Moreover, specific tumour subtypes appear to benefit more from PCM. Costs associated with next‑generation sequencing (NGS) for CGP are decreasing, but targeted therapy itself represents a major cost driver. CGP not only enables prediction of response to treatment, but also resistance, and could thus prevent administration of unnecessary (and costly) therapies. In clinical practice, the presence of clinical frameworks, such as the Recommendations for the Use of NGS for Patients with Metastatic Cancers from the ESMO Precision Medicine Working Group, and the ESMO Scale for Clinical Actionability of Molecular Targets, are essential in appropriately identifying situations where PCM is clinically meaningful, thereby improving its cost‑effectiveness.

Related Articles

Journal Cover

January-2022
Volume 16 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Christofyllakis K, Bittenbring JT, Thurner L, Ahlgrimm M, Stilgenbauer S, Bewarder M and Kaddu‑Mulindwa D: Cost‑effectiveness of precision cancer medicine‑current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review). Mol Clin Oncol 16: 21, 2022
APA
Christofyllakis, K., Bittenbring, J.T., Thurner, L., Ahlgrimm, M., Stilgenbauer, S., Bewarder, M., & Kaddu‑Mulindwa, D. (2022). Cost‑effectiveness of precision cancer medicine‑current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review). Molecular and Clinical Oncology, 16, 21. https://doi.org/10.3892/mco.2021.2453
MLA
Christofyllakis, K., Bittenbring, J. T., Thurner, L., Ahlgrimm, M., Stilgenbauer, S., Bewarder, M., Kaddu‑Mulindwa, D."Cost‑effectiveness of precision cancer medicine‑current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review)". Molecular and Clinical Oncology 16.1 (2022): 21.
Chicago
Christofyllakis, K., Bittenbring, J. T., Thurner, L., Ahlgrimm, M., Stilgenbauer, S., Bewarder, M., Kaddu‑Mulindwa, D."Cost‑effectiveness of precision cancer medicine‑current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review)". Molecular and Clinical Oncology 16, no. 1 (2022): 21. https://doi.org/10.3892/mco.2021.2453